BDBM703968 (S)-6-amino-7-methyl-N-(5,6,7,8- tetrahydroquinoxalin-5-yl)-N-((5- (trifluoromethyl)pyridin-2- yl)methyl)-1,5-naphthyridine-3- carboxamide LCMS [M + 1]+ = 494.2. 1H NMR (400 MHz, MeOD-d4) $#948; = 9.01- 8.71 (m, 2H), 8.56-8.50 (m, 1H), 8.43-8.36 (m, 1H), 8.31-8.02 (m, 2H), 7.89-7.81 (m, 1H), 7.80- 7.71 (m, 1H), 5.36-5.27 (m, 1H), 5.00 (d, J = 16.5 Hz, 1H), 4.24 (d, J = 16.4 Hz, 1H), 3.07- 2.80 (m, 2H), 2.42-2.24 (m, 4H), 2.22-2.00 (m, 2H), 1.96-1.66 (m, 1H)::US20240368153, Example 10-5
SMILES Cc1cc2ncc(C(=O)N(Cc3ccc(C(F)(F)F)cn3)[C@H]3CCCc4nccnc43)cc2nc1N
InChI Key InChIKey=VSRTXQHVPZHROV-UHFFFAOYSA-N
Data 1 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 1 hit for monomerid = 703968
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 1.47E+4nMAssay Description:Table B2: The assay uses recombinant full-length histone H2A as the PRMT5 substrate. Enzymatic transfer of the tritiated methyl group from S-adenosyl...More data for this Ligand-Target Pair
